{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:55:29Z","timestamp":1784566529314,"version":"3.55.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The impact of impaired kidney function on outcomes and treatment benefits of vitamin-K antagonists (VKA) versus direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) has insufficiently been investigated in randomized controlled studies (RCTs). Most studies and registries are either biased due to incomplete enrolment of consecutive patients in large pharma industry sponsored registries, or due to short recruitment periods or incomplete assessment of important variables in national registries.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study uses data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), a retrospective single-center registry of 10,222 consecutive patients with AF presenting to the emergency department of University Hospital of Heidelberg from June 2009 until March 2020. Rates of all-cause mortality, stroke, major bleeding and myocardial infarction (MI) were related to the presence and severity of impaired presenting kidney function, as well as to assigned treatment with VKA vs. DOAC.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The risks for all-cause mortality (HR: 3.26, p&lt;0.001), stroke (HR: 1.58, p&lt;0.001), major bleeding (HR: 2.28, p&lt;0.001) and MI (HR: 2.48, p&lt;0.001) were significantly higher in patients with an eGFR&lt;60 ml\/min at admission and increased with decreasing eGFR. After adjustment for variables of CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>VASc-score, presence of eGFR &lt;60 ml\/min remained as an independent predictor for all-cause mortality, major bleeding and MI. The hazard ratio (HR) for all-cause mortality, major bleedings and MI was significantly lower in patients receiving DOAC compared to VKA.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Findings from our large real-life registry confirm the data from RCTs and extend our knowledge on the effectiveness and safety of DOACs to subjects that were underrepresented in RCTs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0310838","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:26:29Z","timestamp":1727112389000},"page":"e0310838","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of impaired kidney function on outcomes and treatment effects of oral anticoagulant regimes in patients with atrial fibrillation in a real-world registry"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-545X","authenticated-orcid":true,"given":"Christian","family":"Salbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4602-5489","authenticated-orcid":true,"given":"Barbara Ruth","family":"Milles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Hund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-6538","authenticated-orcid":true,"given":"Moritz","family":"Biener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mueller-Hennessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Katus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Giannitsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"25","key":"pone.0310838.ref001","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.","volume":"123","author":"A Alonso","year":"2011","journal-title":"Circulation"},{"key":"pone.0310838.ref002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-019-0211-y","article-title":"Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study.","volume":"17","author":"EK Laugesen","year":"2019","journal-title":"Thromb J."},{"issue":"10225","key":"pone.0310838.ref003","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"P Cockwell","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"pone.0310838.ref004","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"AN Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"pone.0310838.ref005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"JB Olesen","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0310838.ref006","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.","volume":"127","author":"JP Piccini","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"pone.0310838.ref007","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0310838.ref008","doi-asserted-by":"crossref","first-page":"e010510","DOI":"10.1161\/JAHA.118.010510","article-title":"Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD\u2014AF Registry.","volume":"8","author":"S Goto","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"pone.0310838.ref009","doi-asserted-by":"crossref","first-page":"e033396","DOI":"10.1161\/JAHA.123.033396","article-title":"Design, Rationale and Initial Findings From HERA-FIB on 10 222 Patients With Atrial Fibrillation Presenting to an Emergency Department Over An 11-Year Period.","author":"C Salbach","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"10075","key":"pone.0310838.ref010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease.","volume":"389","author":"AC Webster","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"pone.0310838.ref011","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"pone.0310838.ref012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"GY Lip","year":"2010","journal-title":"Chest"},{"issue":"5","key":"pone.0310838.ref013","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"issue":"46","key":"pone.0310838.ref014","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"EC O\u2019Brien","year":"2015","journal-title":"Eur Heart J"},{"issue":"20","key":"pone.0310838.ref015","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth Universal Definition of Myocardial Infarction (2018).","volume":"138","author":"K Thygesen","year":"2018","journal-title":"Circulation"},{"issue":"9921","key":"pone.0310838.ref016","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"CT Ruff","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"pone.0310838.ref017","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0310838.ref018","doi-asserted-by":"crossref","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF\u2014TIMI 48 Trial.","volume":"7","author":"CL Fanola","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"pone.0310838.ref019","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0310838.ref020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0310838.ref021","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).","volume":"159","author":"EZ Soliman","year":"2010","journal-title":"Am Heart J"},{"key":"pone.0310838.ref022","doi-asserted-by":"crossref","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","article-title":"Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study","volume":"20","author":"J Sundstrom","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"3 Suppl 1","key":"pone.0310838.ref023","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"73","author":"R Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"pone.0310838.ref024","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.116.022802","article-title":"Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation","volume":"134","author":"J Oldgren","year":"2016","journal-title":"Circulation"},{"key":"pone.0310838.ref025","doi-asserted-by":"crossref","first-page":"1042763","DOI":"10.3389\/fcvm.2022.1042763","article-title":"HAS-BLED vs. ORBIT scores in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis.","volume":"9","author":"X Liu","year":"2022","journal-title":"Front Cardiovasc Med."},{"issue":"7","key":"pone.0310838.ref026","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ehjqcco\/qcab069","article-title":"Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry","volume":"8","author":"M Proietti","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"2","key":"pone.0310838.ref027","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.amjmed.2016.09.012","article-title":"Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice","volume":"130","author":"M Mazurek","year":"2017","journal-title":"Am J Med"},{"issue":"2","key":"pone.0310838.ref028","first-page":"114","article-title":"Evolving quality standards for large-scale registries: the GARFIELD-AF experience","volume":"3","author":"KAA Fox","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"pone.0310838.ref029","doi-asserted-by":"crossref","first-page":"h5876","DOI":"10.1136\/bmj.h5876","article-title":"Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study","volume":"351","author":"L Staerk","year":"2015","journal-title":"BMJ"},{"key":"pone.0310838.ref030","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"JB Olesen","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"pone.0310838.ref031","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"L Friberg","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0310838.ref032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fca-2020-0014","article-title":"GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke","volume":"17","author":"JP Bassand","year":"2021","journal-title":"Future Cardiol"},{"issue":"14","key":"pone.0310838.ref033","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"AJ Camm","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0310838.ref034","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ehjcvp\/pvac042","article-title":"Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care","volume":"9","author":"P Kirchhof","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"pone.0310838.ref035","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11739-021-02799-5","article-title":"Does CHA2DS2-VASc score predict mortality in chronic kidney disease?","volume":"16","author":"C Goudis","year":"2021","journal-title":"Intern Emerg Med"},{"key":"pone.0310838.ref036","first-page":"100532","article-title":"Modified CHA(2)DS(2)-VASc score predicts in-hospital mortality and procedural complications in acute coronary syndrome treated with percutaneous coronary intervention.","volume":"28","author":"A Abugroun","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"pone.0310838.ref037","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjcard.2021.05.004","article-title":"The CHA(2)DS(2)-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation.","volume":"155","author":"GR Marzouka","year":"2021","journal-title":"Am J Cardiol"},{"issue":"22","key":"pone.0310838.ref038","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0310838.ref039","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.","volume":"134","author":"EA Bohula","year":"2016","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T17:26:40Z","timestamp":1727112400000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310838"}},"subtitle":[],"editor":[{"given":"Giulio Francesco","family":"Romiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310838","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}